- February 11, 2021
Questions and Answers - Antitrust: Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns
Today, the European Commission has made commitments offered by Aspen legally binding under EU antitrust rules. Aspen has to reduce its prices in Europe for six critical cancer medicines by 73% on average. In addition, Aspen has to ensure the continued supply of these off-patent medicines for a significant period. These commitments address the Commission's concerns of excessive pricing.
CONTINUE READING ON: ec.europa.eu